Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  AUSTRALIAN SECURITIES EXCHANGE LIMITED  >  Somnomed Limited    SOM   AU000000SOM1

SOMNOMED LIMITED

(SOM)
  Report  
End-of-day quote. End-of-day quote AUSTRALIAN SECURITIES EXCHANGE LIMITED - 08/23
2 AUD   -4.76%
02/21SOMNOMED : Morgans rates SOM as Add
AQ
2018SOMNOMED LIMITED : RIGHTS ISSUE: 1 new share @ 3 AUD for 17 existing shares
FA
2017SOMNOMED : Substancial Shareholder Notice 08.09.2017
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Somnomed Limited : SomnoMed appoints new Head for North Amercian region

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/26/2012 | 09:52pm EDT

SOMNOMED APPOINTS NEW HEAD FOR NORTH AMERICAN REGION

27th September 2012: SomnoMed announced today the appointment of Kien T. Nguyen as President for
SomnoMed Inc., the US subsidiary of SomnoMed Limited.
Kien has a lifelong career in the healthcare industry, working for leading companies such as Stryker Corporation, Kinetic Concepts, Inc. (KCI) and various medical device divisions of Johnson & Johnson. Most recently, he was Vice President and General Manager of OtisMed, a business unit of Stryker Orthopaedics, a division of the $8 billion Stryker Corporation. At KCI, he fulfilled various functional Vice President positions, including Global Portfolio Management, Global Research & Ideation, and Global Marketing of the Active Healing Solutions division, with revenues responsibilities of $1.4 billion. Most of his earlier career was spent with Ethicon, Inc., a Johnson & Johnson company, where he held roles in product development, product marketing, clinical sales and finally as Worldwide Marketing Director for the biosurgical business unit within Johnson & Johnson Wound Management.
"We are very pleased to have been able to gain Kien Nguyen as our new head of our North American business. Kien is an outstanding individual with an impeccable career, focused on strategy development and marketing & sales in medical devices and biological products. His academic background is exemplary with an MBA from Columbia Business School, a doctorate (Neuroscience) from University of Colorado and a Master of Science (Microbiology) from Minnesota State University. His past business successes were based on solid knowledge of the key factors influencing medical specialists and decision makers and his great personality allowing him to attract talent around him and lead a team to success," said Dr. Peter Neustadt, Executive Chairman of SomnoMed Limited.
"This appointment is significant for SomnoMed's business in the US and Canada, being our most important markets. Kien will work closely with me and report to SomnoMed's board on a monthly basis. Over the last three months all directors were directly involved in the recruitment of the President for SomnoMed Inc. and the quality of executives interviewed was outstanding. After an extensive search process all directors were of the opinion that Kien was the candidate of choice and the executive most likely to succeed in building a significant business for our company in North America in the future," said Dr. Neustadt.
Kien was born in Vietnam and came to the US as a young child. As a refugee of the war, he had to take early responsibility for his education, putting himself through college working as a surgical technician at the Mayo Clinic, and earning a Bachelor of Science degree in Genetics and Cell Biology from the University of Minnesota. Post baccalaureate, he joined Lark Sequencing Technologies, Inc., as a molecular biologist. He is married and has two sons.
Kien Nguyen will be based at the North American head office in Frisco, TX. His appointment will take effect on 5 November 2012.
About SomnoMed
SomnoMed is a public company providing diagnostic and treatment solutions for Sleep-related Breathing Disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialized on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent® becoming the state-of-the-art and clinically proven medical oral appliance therapy for obstructive sleep apnea. SomnoDent® is the most comfortable and effective design and treatment solution for over 100,000 patients in 22 countries. For additional information, visit SomnoMed at http://www.somnomed.com.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SOMNOMED LIMITED
05/25SOMNOMED : Makes Progress with New Approvals, Shareholder
AQ
02/21SOMNOMED : Morgans rates SOM as Add
AQ
2018SOMNOMED : Announces Change in Leadership
AQ
2018SOMNOMED LIMITED : RIGHTS ISSUE: 1 new share @ 3 AUD for 17 existing shares
FA
2017SOMNOMED : Substancial Shareholder Notice 08.09.2017
PU
2017SOMNOMED (SOM) | BUY : RSS network shaping up nicely 28.08.2017
PU
2017SOMNOMED : SOM Preliminary Accounts FY17 24.08.2017
PU
2017SOMNOMED : FY17 Investors Presentation 24.08.2017
PU
2017SOMNOMED : Winter 2017 Newsletter
PU
2017SOMNOMED : TDM Substantial Shareholder Notice SOM – 12.5.17
PU
More news
Financials (AUD)
Sales 2020 68,1 M
EBIT 2020 4,92 M
Net income 2020 3,52 M
Finance 2020 7,67 M
Yield 2020 -
P/E ratio 2020 37,2x
P/E ratio 2021 30,0x
EV / Sales2020 1,82x
EV / Sales2021 1,64x
Capitalization 132 M
Chart SOMNOMED LIMITED
Duration : Period :
Somnomed Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SOMNOMED LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 2,39  AUD
Last Close Price 2,10  AUD
Spread / Highest target 18,6%
Spread / Average Target 13,9%
Spread / Lowest Target 9,29%
EPS Revisions
Managers
NameTitle
Neil Verdal-Austin Chief Executive Officer
Peter Neustadt Non-Executive Chairman
Robert Scherini Independent Non-Executive Director
Lee Ausburn Independent Non-Executive Director
Hamish Corlett Director
Sector and Competitors
1st jan.Capitalization (M$)
SOMNOMED LIMITED14.75%89
MEDTRONIC PLC18.55%144 561
BAXTER INTERNATIONAL INC.32.50%44 577
HOYA CORPORATION33.39%30 490
ZIMMER BIOMET HOLDINGS32.19%28 216
TERUMO CORP-46.28%22 996